SG/PUT/GILEAD SCIENCES/70/0.1/17.01.25 | Real-time Bid/Ask 10:11:57 2024-07-08 EDT | ||
| 0.57 EUR / 0.58 EUR | -12.88% |
|
| Current month | +24.53% | ||
| 1 month | -16.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-08 | 0.52 | -21.21% |
| 24-07-05 | 0.66 | +4.76% |
| 24-07-04 | 0.63 | +16.67% |
| 24-07-03 | 0.54 | 0.00% |
| 24-07-02 | 0.54 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 08, 2024 at 02:32 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SY0083 |
| ISIN | DE000SY00835 |
| Date issued | 2024-05-29 |
| Strike | 70 $ |
| Maturity | 2025-01-17 (193 Days) |
| Parity | 10 : 1 |
| Emission price | 0.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.92 € |
|---|---|
| Lowest since issue | 0.46 € |
| Spread | 0.01 € |
| Spread % | 1.72% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.69
USD
Average target price
83.34
USD
Spread / Average Target
+24.96%
- Stock Market
- Warrants
- Warrant
